OBJECTIVES: Clinical trials have reported A1C reductions of 0.7% over 24 weeks for sitagliptin monotherapy and when added to metformin (baseline A1C 8.0% for both). When added to pioglitazone the mean A1C reduction was 0.9% (baseline A1C 8.1%). With monotherapy 45% of patients achieved A1C 7.0%. METHODS: Patient characteristics and real-world effectiveness of sitagliptin were investigated using a large US claims database. Patients with new prescription claims for sitagliptin between 10/1/06 and 3/31/07 and 12 months pre-and post-index eligibility were included (n 3719). Mean (SD) age was 56.0 ( 10.0) and 39% were female. Comorbidities included: hypertension (84%), dyslipidemia (83%), and other cardiovascular disease (25%). The starting dose was 100 mg for 93% of patients. Concomitant antihyperglycemic medications at index ( 100 to 15 days post index) included metformin (58%), thiazolidinediones (41%), sulfonylureas (37%) and insulin (16%). Seven percent had no concomitant antihyperglycemic medications. RESULTS: The mean (SD) number of concomitant medications was 1.9 ( 1.0). Insulin use increased from 16% to 25% (p .0001), in the 12 month post-index period. Other concomitant medications showed little change. The medication possession ratio (days supply/365 days) in patients with 1 prescription claim was 74 29%. Clinical effectiveness was measured in patients with baseline (6 months pre-index -1 month post index) and post-index (60-365 days) A1C data (n 102). Mean (SD) baseline A1C was 7.6% ( 1.0) with an absolute reduction of 0.2% ( 1.1) [mean duration of follow-up 246.0 ( 81.6) days]. Of 72 patients with a baseline A1C 7.0%, 21 (29%) achieved an A1C goal of 7.0%. CONCLUSIONS: This study reports real-world analyses of sitagliptin patient characteristics and effectiveness. Adherence to therapy was similar to that for other oral antihyperglycemic drugs, but mean reduction in A1C and percent to goal were less than in clinical trials, despite an increase in the percent of patients using insulin. The date of the fi rst duloxetine or pregabalin prescription dispensed was defi ned as the index date. All patients selected were diagnosed with DPNP and had continuous enrollment over the 12-month pre-index period. Each patient was classifi ed in the duloxetine or pregabalin cohorts based on the index agent, and all duloxetine or pregabalin prescriptions fi lled over the 12-month follow-up period were examined. We compared the average daily dose of all prescriptions per person, average daily dose in each of the fi rst 10 prescriptions, and percent of daily dose change from previous prescription between duloxetine and pregabalin cohorts. RESULTS: Among 603 duloxetine patients and 1751 pregabalin patients, the average daily doses of all prescriptions were 51.2mg and 179.8mg for duloxetine and pregabalin, respectively. The average daily doses for the 1st and 10th duloxetine scripts were 53.8mg (95% Confidence Interval (CI): 52.4, 55.2) and 64.9mg, while the numbers were 166mg (95% CI: 162, 170) and 264.3mg (95% CI: 244.1, 284.4) for pregabalin. The changes in daily doses from previous prescription were 0.2-4.0% for duloxetine and 0.8-12.5% for pregabalin, respectively. The percentage of change in daily dose from the 1st to 10th prescription was signifi cantly higher for pregabalin (59.2%) than for duloxetine (20.7%) (p 0.05). CONCLUSIONS: DPNP patients on duloxetine or pregabalin experienced very different dosing patterns. The average daily dose for duloxetine was relatively stable over time, while pregabalin patients had signifi cant dose escalation over the 12-month follow-up period.
PDB8 COMPARISON OF DOSING PATTERNS OF DULOXETINE AND PREGABALIN AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN
To compare dosing patterns between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain (DPNP). METHODS: Using a large administrative claims database in the United States, we examined commercially insured individuals aged 18-64 who dispensed duloxetine or pregabalin in 2006. The date of the fi rst duloxetine or pregabalin prescription dispensed was defi ned as the index date. All patients selected were diagnosed with DPNP and had continuous enrollment over the 12-month pre-index period. Each patient was classifi ed in the duloxetine or pregabalin cohorts based on the index agent, and all duloxetine or pregabalin prescriptions fi lled over the 12-month follow-up period were examined. We compared the average daily dose of all prescriptions per person, average daily dose in each of the fi rst 10 prescriptions, and percent of daily dose change from previous prescription between duloxetine and pregabalin cohorts. RESULTS: Among 603 duloxetine patients and 1751 pregabalin patients, the average daily doses of all prescriptions were 51.2mg and 179.8mg for duloxetine and pregabalin, respectively. The average daily doses for the 1st and 10th duloxetine scripts were 53.8mg (95% Confidence Interval (CI): 52.4, 55.2) and 64.9mg, while the numbers were 166mg (95% CI: 162, 170) and 264.3mg (95% CI: 244.1, 284.4) for pregabalin. The changes in daily doses from previous prescription were 0.2-4.0% for duloxetine and 0.8-12.5% for pregabalin, respectively. The percentage of change in daily dose from the 1st to 10th prescription was signifi cantly higher for pregabalin (59.2%) than for duloxetine (20.7%) (p 0.05). CONCLUSIONS: DPNP patients on duloxetine or pregabalin experienced very different dosing patterns. The average daily dose for duloxetine was relatively stable over time, while pregabalin patients had signifi cant dose escalation over the 12-month follow-up period.
PDB9 THE EFFECTS OF SUSTAINED-RELEASE GLIPIZIDE VERSUS GLICLAZIDE FOR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
Wang L g 1 , Li Y 2 1 Sichuan University, Chengdu, Sichuan, China, 2 West China Hospital, Sichuan University, Chengdu, China OBJECTIVES: There are currently many kinds of sulphonylurea agents taken as the fi rst-line drugs for patients with diabetes. As the second-generation sulfonylureas, we try to explore the comparative effi cacy and safety of sustained-release glipizide and gliclazide for type 2 diabetes mellitus. METHODS: A systematic review of randomized controlled trials (RCTs) was conducted. PUBMED, EMBASE, The Cochrane Library, three Chinese Databases (CBM, CNKI, and VIP), as well as the citations or reference lists were searched from their inception to July 31, 2008. The pharmaceutical companies were contacted for unpublished studies. Trial selection, quality assessment and data extraction were performed by two reviewers independently. We pooled the trial data using the random-effect model and explored the heterogeneity by the pre-specifi ed variables. RESULTS: Only two trials (n 190) compared the extendedrelease glipizide with gliclazide based on the treatment of metformin or acarbose and diet control. The quality of included trials was poor. Only randomized trials were mentioned without detailed information on the methods of generating randomization sequences, concealment allocation, and blinding. The durations of follow-up(12 weeks) were too short to obtain the long-term effects of the diabetes-related morbidity and mortality. Both sustained-release glipizide and gliclazide had signifi cantly reduced HbA1c, fasting and postprandial blood glucose from baseline to the end of treatment. However, there was no signifi cant difference between groups, including the changes of HbA1c (weighted mean difference 0.13, 95%CI 0.21 to 0.46), fasting blood glucose ( 0.07 [ 0.67, 0.52]), and postprandial blood glucose (1.40 [ 0.80, 3.60] ). There is similar safe profi les in hypoglycemia, changes of lipid and body weight, and liver and renal functions. CONCLUSIONS: The limited evidence showed that both sustained-release glipizide and gliclazide are effective in glucose control with similar effects and safe profi le. More high-quality RCTs are expected to explore the effects of different sulfonylurea agents.
PDB10 A COMPARISON OF ECONOMIC OUTCOMES BETWEEN ADHERENT AND NONADHERENT PATIENTS TREATED WITH ORAL ANTIDIABETIC MEDICATIONS
Hansen RA 1 , Farley JF 1 , Droege M 2 , Maciejewski ML 3 1 University of North Carolina, Chapel Hill, NC, USA, 2 Takeda Pharmaceuticals North America, Inc, Deerfi eld, IL, USA, 3 Center for Health Services Research in Primary Care, Durham, NC, USA OBJECTIVES: Health care costs for adherent patients were compared with costs for nonadherent patients in a cohort with diabetes mellitus taking metformin, sulfonylureas, or pioglitazone. METHODS: Using both, the commercial and Medicare supplemental MEDSTAT MarketScan research databases, a retrospective cohort study identifi ed 108,592 continuously insured patients 18 to 90 years of age with diabetes mellitus (ICD-9-CM 250.xx) using metformin, sulfonylureas, or pioglitazone monotherapy during 2003. Adherence was calculated in 2004 and 2005 using a medication possession ratio, and dichotomized at 80% to indicate adherence. Total health care costs included insurer payments and patient cost-sharing from medical (inpatient, outpatient) and prescription drug claims. Diabetes-specifi c costs included pharmacy claims for any diabetes drug and medical claims containing a primary diagnosis of diabetes or a diabetes complication. Multivariate analysis was conducted to adjust for potential confounders. RESULTS: During the initial year of follow-up, the proportion of patients adherent to treatment were 57%, 61%, and 59% for metformin, sulfonylureas, and pioglitazone, respectively. Annual unadjusted total health care costs were consistently lower for adherent patients than for non-adherent patients ($1470 less for metformin users, $3734 less for sulfonylurea users, and $3477 for pioglitazone users). In the multivariate models, total health care costs and diabetes specifi c health care costs respectively were $846 (95% CI $747 to $945) and $55 (95% CI $33 to $77) per year lower for adherent patients compared to nonadherent patients. The adjusted annual adherence-related cost difference was $336 for metformin (95% CI $216 to $456), $1509 for sulfonylureas (95% CI $1339 to $1679), and $1,140 for pioglitazone (95% CI $793 to $1486). Annual cost differences were larger among Medicare plans compared with commercial insurance plans ($2220 lower vs $65 higher, respectively). CONCLUSIONS: Adherence with oral diabetes medications results in overall health care cost-savings. Both sulfonylureas and pioglitazone were associated with larger total cost-savings than metformin. A Cox proportional hazards model was employed to examine the association between time to DN/CRF diagnosis and exposure to ACEI or ARB. The confounders adjusted in the model included patient socio-demographics, co-morbidities, and comedications. RESULTS: The fi nal cohort consisted of 427,124 patients with a mean age of 76 years. Majority of the patients were males (97.76%), whites (83.83%), in the age group of 76 to 85 years (48.32%). Cardiovascular comorbidities were common, with almost 80% of patients having hypertension, ischemic heart disease (IHD; 34%), and Chronic Heart Failure (CHF; 26%). A total of 2.76% of the patients from the fi nal cohort developed DN/CRF. Multivariable analysis revealed that exposure to ACEI and ARBs is associated with increased risk of DN/CRF by 42% (95% CI 1.354-1.481) and 51% (95% CI 1.37-1.656) respectively. Many co-morbid conditions (Hypertension, IHD, CHF) and all the co-medications adjusted in the model were signifi cantly associated with increased risk of DN/CRF, with most prominent association found in patients using insulin, antihypertensives, and diuretics. CONCLUSIONS: Our study indicates that the use of agents that inhibit ReninAngiotensin-Aldosterone System (RAAS) do not prevent the development of DN/CRF.
PDB11 EFFECT OF ACE INHIBITORS AND ARBS ON INCIDENCE OF RENAL DISEASE IN ELDERLY PATIENTS WITH DIABETES

